COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Enlaza Therapeutics, the first covalent biologic platform company, today announced its official launch with the closing of $61 million in seed financing. The ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, ...

Treating cancer with medicines that tightly attach to their targets via covalent bonds is not a new concept in drug discovery, but it is picking up pace. Some companies are trying to improve this ...

SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced ...

Doron Therapeutics, a clinical-stage biotechnology company developing novel biologics for musculoskeletal diseases, today announced that the initial patients have been dosed in its Phase 3 clinical ...

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026Budoprutug clinical trials ongoing in pMN, ...

Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025 Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation ...

Primrose Bio’s advanced technology for manufacturing nucleic acids and proteins makes it the partner of choice for pharma companies developing new vaccines, therapeutics and bio-based products.

The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.